404 results about "Neurological disorder" patented technology

Systems and methods for computer modeling in medicine. A sort of period table of medical models is described for personalized diagnostics, prognostics and therapeutics, including at least 80 major categories of medical models. Generative artificial intelligence and geometric deep learning techniques, and algorithms including 2D and 3D graph machine learning and GenAI algorithms, are described, tailored and applied to diagnostic disease description, prognostic prediction and therapeutic development and management, including generation of novel synthetic drugs. The AI and machine learning techniques and algorithms are applied to understand each individual's genetic, RNA and protein anomalies that represent the source of many unique patient diseases. AI-enabled software agents assist physicians and researchers in building patient medical models. Several personalized medicine applications of individualized medical modeling include cardiovascular disease, cancer, neurological disorders, immune system disorders and genetic diseases.

The present application relates to heterobicyclic compounds having glucagon-like peptide receptor (GLP-1R) agonist activity, processes for their preparation, pharmaceutical compositions comprising them and their use as GLP-1R agonists or for the treatment or prophylaxis of GLP-1R associated diseases or disorders. In particular, the compounds of the present application are useful for body weight management, for lowering blood sugar and / or for the treatment or prevention of diabetes, diabetic complications, obesity, overweight, dyslipidemia, fatty liver diseases (e.g., non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)), metabolic diseases, cardiovascular diseases, nervous system disorders, mental disorders, kidney diseases, etc. , gastrointestinal diseases, autoimmune diseases, inflammatory diseases, lung diseases, hypothalamic-pituitary-gonad axis related diseases or disorders, cancers and the like.

The present disclosure provides double stranded oligonucleotides, compositions, and methods relating thereto. The present disclosure encompasses the recognition that structural elements of double stranded oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, and / or stereochemistry (e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages), and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., RNA interference (RNAi) activity, Ago2 loading, thermal stability, in vivo stability, delivery to tissues and into cells, etc. The present disclosure also provides methods for treatment of diseases, e.g., hepatic diseases, central nervous system (CNS) diseases, etc., using provided double stranded oligonucleotide compositions, for example, in RNA interference.

The invention relates to a phenylpropanoid compound as well as a preparation method and application thereof, in particular to a phenylpropanoid compound extracted from pleione bulbus pseudobulb as well as a preparation method and application thereof, and belongs to the technical field of medicines. The invention provides a method for preparing 10 new compounds from pleione bulbocodioides pseudobulb as a raw material for the first time, systematically evaluates the anti-neuroinflammation activity of pleione bulbocodioides pseudobulb, and clarifies the application of pleione bulbocodioides pseudobulb in development and treatment of central nervous system diseases. According to the invention, abnormally activated BV-2 microglial cells induced by LPS (Lipopolysaccharide) are adopted, and the NO release amount is taken as an index, so that the effect of the compound 1-10 on inhibiting excessive activation of the microglial cells is preliminarily evaluated. The result shows that the novel compounds 1-10 can inhibit the release of LPS-induced BV-2 microglial cell NO. Therefore, the compound prepared in the invention can be applied to development of drugs for treating central nervous system diseases.

Described herein are therapeutic electrical muscle stimulation (EMS) apparatuses for the detection, diagnosis, treatment or prevention of a neurological disorder. These apparatuses (including EMS suits, user interfaces, and control systems, etc.) and methods may be used as part of a therapeutic or non-therapeutic procedure. For example, these methods and apparatuses may be part of an exercise or fitness and / or may be used as part of a therapy, such as in particular for physiotherapy and / or for treatment of a condition or a disease.

The invention provides a compound as shown in a formula I which can be used as a sodium channel regulator, and a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof. The invention also provides a pharmaceutical composition containing the compound and the stereoisomer, the tautomer or the pharmaceutically acceptable salt thereof and a carrier or excipient, and a pharmaceutical application of the pharmaceutical composition as a NaV1.8 inhibitor (such as pain, respiratory diseases, neurological disorders, mental diseases and the like).

The present invention provides CXCR4 inhibitors of formula (I) and pharmaceutically acceptable salts thereof, as well as methods of using them in the treatment of neurological and CNS diseases, disorders, and conditions. The provided compounds are inhibitors of CXCR4 and are therefore useful for treating one or more disorders associated with CXCR4 activity. Thus, in certain embodiments, the present invention provides a method for treating a CXCR4-mediated disorder, comprising administering to a patient in need thereof a CXCR4 inhibitor described herein, such as a compound of formula I or a pharmaceutically acceptable salt thereof. Certain embodiments of the present invention are directed to the use of CXCR4 inhibitors that, when administered to a subject, cross the blood-brain barrier (BBB) ​​and enter the brain and central nervous system (CNS). JPEG2026502774000083.jpg3135

The present invention relates to novel phosphate ester compounds of formula I for use in the treatment of central nervous system (CNS) diseases. Furthermore, the present invention provides an improved process for obtaining the compound of formula (I) in high yield and high purity. The novel phosphate ester compounds of formula-I are useful in the treatment of neurological, neuropsychiatric, metabolic and neurodevelopmental disorders.

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

The present invention relates to a novel compound and a pharmaceutical composition comprising the same as an active ingredient. The novel compound, which is obtained by means of carrying out chemical modification in a mother structure showing excellent AMP-activated protein kinase (AMPK) activation efficacy and in silico binding capacity, enables effective prevention or treatment of degenerative neurological disorders by means of effectively inducing AMP-activated protein kinase enzyme activation.

The present invention relates to variable domains (VHHs) of camelid heavy chain molecules that bind to TfR, conjugate compounds containing such VHH molecules, and their use for, for example, transporting molecules for pharmaceutical purposes to cells and organs in pathological conditions in the CNS or PNS, including cancer.

The present invention relates to a composition for preventing, ameliorating or treating central nervous system diseases, comprising a peptidomimetic compound (NIP001) containing hydrophilic arginine and a hydrophobic histidine derivative. In the present invention, the peptidomimetic compound comprising hydrophilic arginine and a hydrophobic histidine derivative was confirmed to effectively inhibit inflammatory responses in microglia and to have the effect of improving the cognitive function of mice with scopolamine-induced cognitive impairment, and thus can be used as a targeted therapeutic agent for central nervous system diseases.

Disclosed are novel compounds that are antagonists of the human GPR39 protein. Disclosed are pharmaceutical compositions of antagonists of the human GPR39 protein and methods of use. In particular, disclosed herein are methods of using the antagonists to treat diseases or conditions, including cardiovascular conditions, endocrine system and hormone disorders, cancer disorders, metabolic diseases, gastrointestinal and liver diseases, blood disorders, neurological disorders, and respiratory diseases.

To provide a novel tetracycline derivative having reduced antimicrobial activity for use in treating disorders of the central nervous system.SOLUTION: Provided are novel molecules comprising a modified tetracycline molecule including Deamino Diacetyl Minocycline, Methyl Ether Minocycline, Ethyl Ether Minocycline, Propyl Ether Minocycline, Butyl Ether Minocycline, Butyl Ether Monoacetyl Minocycline, Butyl Ether Diacetyl Minocycline, Butyl Ether Triacetyl Minocycline, or Butyl Ether Tetra Acetyl Minocycline, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, and tautomers thereof, and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders.SELECTED DRAWING: None

The present invention relates to a polynucleotide sequence comprising a 5' untranslated region (5' UTR), a messenger RNA (mRNA) coding region, and a 3' untranslated region (3' UTR), wherein the 5' UTR and / or 3' UTR are modified. The invention further encompasses compositions and methods for delivering the modified polynucleotide to a subject in need thereof for the treatment or prevention of neurological disorder or neurobiological psychotic disorders.

Compositions and methods are provided for modulating cellular activity using engineered receptors, polynucleotides encoding the engineered receptors, and gene therapy vectors comprising polynucleotides encoding the engineered receptors. These compositions and methods find particular use in modulating neuronal activity, for example, in treating disease or studying neural circuits.

The disclosed invention is a method for mapping glutathione deficiency and / or mitochondria dysfunction in disease states, utilizing glutathione and its precursors as imaging tracers in conjunction with medical imaging techniques, particularly magnetic resonance imaging. The innovation involves administering glutathione or glutathione-increasing interventions, such as oral liposomal reduced glutathione, to enhance imaging accuracy. The proposed methodology aims to identify and monitor regions of depleted reduced glutathione (GSH) in various organs and tissues. The maps generated through this process provide valuable biomarkers for toxic exposure, early biological effects, and health risks. The approach is versatile, offering applications in mental health, neurological disorders, inflammation, organ dysfunction, and personalized treatment and risk assessments.

Particles are provided that include a liposome having a negatively charged outer surface and a lipid-drug conjugate, a first layer of cationic polymer such as poly-L-arginine (PLR), that is non-covalently associated with the negatively charged outer surface of the liposome, and a second layer having a mixture of an anionic polymer and polyethylene glycol modified anionic polymer that is non-covalently associated with the first layer. The particles can be formulated as pharmaceutical compositions that are useful in methods that target neurological disorders such as brain tumors and other neurological diseases, and that can deliver and / or transport therapeutic drugs across the blood brain barrier.

Disclosed herein are methods for treating a disease or disorder of the central or peripheral nervous system by administering to a subject in thereof an agent capable of modulating the activity or expression of bone morphogenetic protein and activin membrane-bound inhibitor (BAMBI). Additionally, methods for screening agents capable of modulating the activity or expression of BAMBI are disclosed.

This invention relates to formulations of compound (I) (BNC2IO), an allosteric modulator of the a7-nicotinic receptor with non-sedative anxiolytic effects; specifically, solid dispersions, methods of manufacture thereof, and therapeutic methods and uses in the treatment of diseases of the central nervous system thereof.

Compositions and methods for treating neurological conditions are provided. The present invention provides a pharmaceutical composition comprising a dopamine reuptake inhibitor or dopamine agonist, an adrenergic receptor antagonist, and a pharmaceutically acceptable carrier, and a method for treating a neurological disorder by administering the composition.

Provided in the present invention are a compound as represented by formula I which can be used as a sodium channel modulator, and a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof. Further provided are a pharmaceutical composition containing the compound and the stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, and a carrier or an excipient, and the pharmaceutical use thereof as an NaV1.8 inhibitor (against, for example, pain, respiratory diseases, neurological disorders, and mental diseases).

The present invention provides compositions and methods for treating or preventing nervous system diseases or disorders of the central nervous system (e.g., storage disorders, lysosomal storage disorders, neurodegenerative diseases, etc.) by reconstituting cerebromyelocytes and microglia upon transplantation of hematopoietic cells enriched in microglia reconstitution potential. The present invention also provides compositions and methods for ablating and reconstituting microglia. The present invention provides, for example, a method of delivering hematopoietic stem cells (HSCs) to a subject, comprising administering the HSCs by intracerebroventricular injection (ICV) in combination with ablation pretreatment.

Sublingual or buccal dosage forms comprise at least one antioxidant compound, such as N-acetyl cysteine (NAC), or a pharmaceutically acceptable salt thereof. The sublingual or buccal dosage forms are administered for treating central nervous system (CNS) disorders, such as traumatic brain injury or stroke.

Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Optical coherence tomography (OCT) data can be analyzed with neural networks trained on OCT data and known clinical outcomes to make more accurate predictions about the development and progression of retinal diseases, central nervous system disorders, and other conditions. The methods take 2D or 3D OCT data derived from different light source configurations and analyze it with neural networks that are trained on OCT images correlated with known clinical outcomes to identify intensity distributions or patterns indicative of different retina conditions. The methods have greater predictive power than traditional OCT analysis because the invention recognizes that subclinical physical changes affect how light interacts with the tissue matter of the retina, and these intensity changes in the image can be distinguishable by a neural network that has been trained on imaging data of retinas.